Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Addition of Olanzapine to Standard CINV Prophylaxis in Hematopoietic Stem Cell Transplant

NCT04535141 is registered in ClinicalTrials.gov with UNC Lineberger Comprehensive Cancer Center as lead sponsor.

NCT NCT04535141
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04535141 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Addition of Olanzapine to Standard CINV Prophylaxis in Hematopoietic Stem Cell Transplant
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Phase
Phase 3
Overall status
Completed
Start date
August 18, 2020
Completion date
April 11, 2022
Enrollment
91 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced nausea and vomiting